AffiliationDepartments of Radiotherapy and Clinical Pharmacology, Christie Hospital and Holt Radium Institute, Withington, Manchester, UK
MetadataShow full item record
AbstractThirty-four patients with metastatic breast carcinoma were treated with the following combination: methotrexate 60 mg/m2 i.v. days 1 and 8,5-fluorouracil 500 mg/m2 i.v. days 1 and 8, cyclophosphamide 100 mg/m2 daily for 14 days, and prednisolone 25 mg b.d. by mouth daily for 14 days. In 21/34 (62%) patients regression of tumour was maintained for at least three months and in six (18%) this was complete. The median duration of response was 15 months (range 6--33) and there was a significant difference in survival between responders and non-responders (P<0.01). Toxicity was acceptable although dose reduction was necessary in eight patients and in three patients treatment had to be discontinued.
CitationChemotherapy of metastatic carcinoma of the breast. 1980, 31 (4):433-6 Clin Radiol
- Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin.
- Authors: Creech RH, Catalano RB, Harris DT, Engstrom PF, Grotzinger PJ
- Issue date: 1979 Jan
- Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
- Authors: Hainsworth JD, Jolivet J, Birch R, Hopkins LG, Greco FA
- Issue date: 1997 Feb 15
- [Combination chemotherapy in metastatic breast cancer].
- Authors: Kuten A, Lev L, Mohaliver J, Robinson E
- Issue date: 1981 Feb 1
- Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
- Authors: Mariani G, Petrelli F, Zambetti M, Moliterni A, Fasolo A, Marchiano A, Valagussa P, Gianni L
- Issue date: 2006 Oct
- Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity.
- Authors: Hirshaut Y, Kesselheim H
- Issue date: 1983 Jun 1